Sept. 28 Quick Takes: Biogen gains $1.4B on aducanumab update; plus Zai, XtalPi, InventisBio, Galecto, Innovent, Galapagos-Gilead, Biocytogen and ACT Accelerator

FDA moving quickly on Biogen’s aducanumab 
Biogen Inc. (NASDAQ:BIIB) added $1.4 billion in market cap Monday, as its shares rose $8.73 (3.2%) to $282.04, after FDA said it will hold an advisory committee meeting on Nov. 6 to discuss anti-amyloid therapy aducanumab to treat Alzheimer's disease. The timing of the meeting suggests a decision on the therapy, which was granted Priority Review in August, could come earlier than its PDUFA date of March 7.

Zai climbs in first Hong Kong trading session
Shares of Zai Lab Ltd. (NASDAQ:ZLAB; HKEX:9688) rose HK$48 to HK$610 in Hong Kong on Monday, its first day of trading as a dual-listed company. The cross-border licensing company had raised HK$5.9 billion ($776.1 million) by pricing its Hong Kong offering last week at HK$562 per share, which corresponds to a price per NASDAQ ADS of $72.52. On NASDAQ, Zai rose $3.39 to $82.72 on Monday (see "First Pure Biotech to List Directly on Hong Kong's Main Board")...